Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.93
MKGAY's Cash to Debt is ranked higher than
67% of the 921 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. MKGAY: 0.93 )
MKGAY' s 10-Year Cash to Debt Range
Min: 0.59   Max: No Debt
Current: 0.93

Equity to Asset 0.45
MKGAY's Equity to Asset is ranked higher than
58% of the 842 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. MKGAY: 0.45 )
MKGAY' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.61
Current: 0.45

0.27
0.61
F-Score: 6
Z-Score: 2.02
M-Score: -2.47
WACC vs ROIC
7.77%
22.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 15.87
MKGAY's Operating margin (%) is ranked higher than
85% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.37 vs. MKGAY: 15.87 )
MKGAY' s 10-Year Operating margin (%) Range
Min: 2.84   Max: 19.54
Current: 15.87

2.84
19.54
Net-margin (%) 10.70
MKGAY's Net-margin (%) is ranked higher than
81% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. MKGAY: 10.70 )
MKGAY' s 10-Year Net-margin (%) Range
Min: 2.91   Max: 49.88
Current: 10.7

2.91
49.88
ROE (%) 21.14
MKGAY's ROE (%) is ranked higher than
94% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. MKGAY: 21.14 )
MKGAY' s 10-Year ROE (%) Range
Min: 3.95   Max: 56.59
Current: 21.14

3.95
56.59
ROA (%) 10.77
MKGAY's ROA (%) is ranked higher than
91% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. MKGAY: 10.77 )
MKGAY' s 10-Year ROA (%) Range
Min: 2.33   Max: 30.58
Current: 10.77

2.33
30.58
ROC (Joel Greenblatt) (%) 98.61
MKGAY's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.08 vs. MKGAY: 98.61 )
MKGAY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 8.06   Max: 53.26
Current: 98.61

8.06
53.26
Revenue Growth (3Y)(%) 3.80
MKGAY's Revenue Growth (3Y)(%) is ranked higher than
69% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. MKGAY: 3.80 )
MKGAY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 15.8
Current: 3.8

0
15.8
EBITDA Growth (3Y)(%) 4.60
MKGAY's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. MKGAY: 4.60 )
MKGAY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 14
Current: 4.6

0
14
EPS Growth (3Y)(%) 24.20
MKGAY's EPS Growth (3Y)(%) is ranked higher than
89% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. MKGAY: 24.20 )
MKGAY' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 54.5
Current: 24.2

0
54.5
» MKGAY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MKGAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.70
MKGAY's P/E(ttm) is ranked higher than
91% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.40 vs. MKGAY: 18.70 )
MKGAY' s 10-Year P/E(ttm) Range
Min: 10.19   Max: 261.35
Current: 18.7

10.19
261.35
Forward P/E 6.66
MKGAY's Forward P/E is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.57 vs. MKGAY: 6.66 )
N/A
PE(NRI) 18.90
MKGAY's PE(NRI) is ranked higher than
92% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.00 vs. MKGAY: 18.90 )
MKGAY' s 10-Year PE(NRI) Range
Min: 10.19   Max: 261.35
Current: 18.9

10.19
261.35
P/B 1.20
MKGAY's P/B is ranked higher than
93% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. MKGAY: 1.20 )
MKGAY' s 10-Year P/B Range
Min: 0.35   Max: 1.2
Current: 1.2

0.35
1.2
P/S 3.92
MKGAY's P/S is ranked higher than
64% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.26 vs. MKGAY: 3.92 )
MKGAY' s 10-Year P/S Range
Min: 0.59   Max: 7.96
Current: 3.92

0.59
7.96
PFCF 21.80
MKGAY's PFCF is ranked higher than
92% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 639.25 vs. MKGAY: 21.80 )
MKGAY' s 10-Year PFCF Range
Min: 5.92   Max: 24.05
Current: 21.8

5.92
24.05
POCF 16.85
MKGAY's POCF is ranked higher than
89% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 37.05 vs. MKGAY: 16.85 )
MKGAY' s 10-Year POCF Range
Min: 3.04   Max: 17.37
Current: 16.85

3.04
17.37
EV-to-EBIT 3.92
MKGAY's EV-to-EBIT is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.20 vs. MKGAY: 3.92 )
MKGAY' s 10-Year EV-to-EBIT Range
Min: 2.9   Max: 114.2
Current: 3.92

2.9
114.2
Shiller P/E 38.60
MKGAY's Shiller P/E is ranked higher than
80% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.29 vs. MKGAY: 38.60 )
MKGAY' s 10-Year Shiller P/E Range
Min: 10.43   Max: 43.36
Current: 38.6

10.43
43.36
Current Ratio 1.59
MKGAY's Current Ratio is ranked higher than
61% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. MKGAY: 1.59 )
MKGAY' s 10-Year Current Ratio Range
Min: 0.85   Max: 2.24
Current: 1.59

0.85
2.24
Quick Ratio 1.34
MKGAY's Quick Ratio is ranked higher than
64% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. MKGAY: 1.34 )
MKGAY' s 10-Year Quick Ratio Range
Min: 0.53   Max: 1.62
Current: 1.34

0.53
1.62
Days Inventory 86.53
MKGAY's Days Inventory is ranked higher than
86% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. MKGAY: 86.53 )
MKGAY' s 10-Year Days Inventory Range
Min: 162.19   Max: 272.47
Current: 86.53

162.19
272.47
Days Sales Outstanding 36.18
MKGAY's Days Sales Outstanding is ranked higher than
92% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. MKGAY: 36.18 )
MKGAY' s 10-Year Days Sales Outstanding Range
Min: 58.87   Max: 102.54
Current: 36.18

58.87
102.54

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.16
MKGAY's Dividend Yield is ranked lower than
57% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.42 vs. MKGAY: 1.16 )
MKGAY' s 10-Year Dividend Yield Range
Min: 0.68   Max: 5.19
Current: 1.16

0.68
5.19
Dividend Payout 0.24
MKGAY's Dividend Payout is ranked higher than
88% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MKGAY: 0.24 )
MKGAY' s 10-Year Dividend Payout Range
Min: 0.23   Max: 1.79
Current: 0.24

0.23
1.79
Dividend growth (3y) 15.80
MKGAY's Dividend growth (3y) is ranked higher than
87% of the 364 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. MKGAY: 15.80 )
MKGAY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 15.8
Current: 15.8

0
15.8
Yield on cost (5-Year) 1.20
MKGAY's Yield on cost (5-Year) is ranked lower than
59% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.62 vs. MKGAY: 1.20 )
MKGAY' s 10-Year Yield on cost (5-Year) Range
Min: 0.68   Max: 5.19
Current: 1.2

0.68
5.19

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 33.30
MKGAY's Price/Tangible Book is ranked lower than
58% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. MKGAY: 33.30 )
MKGAY' s 10-Year Price/Tangible Book Range
Min: 1.41   Max: 24.9
Current: 33.3

1.41
24.9
Price/DCF (Projected) 2.00
MKGAY's Price/DCF (Projected) is ranked higher than
86% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.40 vs. MKGAY: 2.00 )
MKGAY' s 10-Year Price/DCF (Projected) Range
Min: 1.05   Max: 1.74
Current: 2

1.05
1.74
Price/Median PS Value 1.10
MKGAY's Price/Median PS Value is ranked higher than
83% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. MKGAY: 1.10 )
MKGAY' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 1.09
Current: 1.1

0.26
1.09
Price/Peter Lynch Fair Value 0.80
MKGAY's Price/Peter Lynch Fair Value is ranked higher than
98% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MKGAY: 0.80 )
MKGAY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.48   Max: 4.07
Current: 0.8

0.48
4.07
Price/Graham Number 4.10
MKGAY's Price/Graham Number is ranked higher than
71% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. MKGAY: 4.10 )
MKGAY' s 10-Year Price/Graham Number Range
Min: 0.48   Max: 4.64
Current: 4.1

0.48
4.64
Earnings Yield (Greenblatt) 25.90
MKGAY's Earnings Yield (Greenblatt) is ranked higher than
98% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MKGAY: 25.90 )
MKGAY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 34.9
Current: 25.9

0.9
34.9
Forward Rate of Return (Yacktman) 40.94
MKGAY's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 520 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. MKGAY: 40.94 )
MKGAY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 7   Max: 52.4
Current: 40.94

7
52.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:LSE:0NZZ, TKPYY, TEVA, AGN, FRX » details
Traded in other countries:0O14.UK, MER.Switzerland, MRK.Germany,
Merck KGaA is a pharmaceutical and chemical company. It operates as a manufacturer of standard and specialty chemicals for the laboratory and industry. he Company researches drugs in the areas oncology and neurodegenerative as well as autoimmune and inflammatory diseases. The Company operate its businesses in four divisions: Merck Serono (prescription medicines), Consumer Health (over-the-counter pharmaceuticals), Performance Materials (high-tech chemicals) and Merck Millipore (products for pharmaceutical research and biotechnology).:. Within the Merck Serono division, the Company researches on therapeutic areas and prescription drugs of chemical and biotechnological origin. The Consumer Health division comprises the over-the-counter products for preventive health care and self-treatment of minor ailments. The Merck Serono and Consumer Health divisions form together the Company's Pharmaceutical business sector. The Merck Millipore division comprises the activities of the Millipore Corporation. The Performance Materials division consists mainly of the Liquid Crystals and Pigments & Cosmetics business units. The Company also markets cardiovascular, fertility, endocrinology, and over-the-counter products as well as products for flat screens and the pharmaceutical, food, cosmetics, packaging, and coatings.
» More Articles for MKGAY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Merck Wins 2015 German Industry Innovation Award Mar 22 2015
Merck Supports Schistosomiasis Education in Mozambique Mar 21 2015
VWR Funding, Inc. -- Moody's upgrades VWR's CFR to B1, rates new Euro senior notes B3; outlook... Mar 17 2015
Merck Places U.S. Bond Amounting to US$ 4.0 Billion Mar 17 2015
Merck Serono and Illumina Enter Strategic Collaboration for Diagnostics in Oncology Mar 10 2015
Merck Serono and Opexa Amend Agreement to Support Ongoing Development of Tcelna (imilecleucel-T) for... Mar 09 2015
Merck Employees Benefit From Company Success Mar 04 2015
Merck Finishes Year of Key Strategic Moves with Record Figures Mar 03 2015
Ralph R. Dammel from Merck receives the Frits Zernike Award for Microlithography at SPIE 2015 Feb 24 2015
Merck Serono and Sysmex Inostics Announce First Liquid Biopsy RAS Biomarker Testing Center Opens:... Feb 20 2015
Merck presents next-generation lithography and patterning solutions at SPIE 2015 Feb 18 2015
Merck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for... Feb 13 2015
Merck and FlexEnable take major step forward in Plastic Liquid Crystal Display technology Feb 11 2015
Ex-Merck analyst facing insider trading charges to plead guilty -lawyer Feb 09 2015
Merck Millipore Announces Agreement with Precision Biologics, Inc. to Provide Upstream Process... Feb 02 2015
Merck Repatriates Diabetes and Thyroids Portfolio in Russia to Continue to Drive Emerging Markets... Feb 02 2015
Merck Announces Personnel Changes in Finance Function Jan 30 2015
Merck Millipore Introduces New High-Performance Water Purification Systems with 24/7 Real-Time... Jan 28 2015
Merck KGaA Presents Liquid Crystal Window Technology at BAU 2015 Jan 20 2015
Merck Presents Liquid Crystal Window Technology at BAU 2015 Jan 15 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK